^
CANCER:
Myelodysplastic Syndrome
No biomarker
MDS
decitabine/cedazuridine
Sensitive
:
A1
No biomarker
MDS
luspatercept-aamt
Sensitive
:
A1
Chr del(5q)
MDS
lenalidomide
Sensitive
:
A1
No biomarker
MDS
azacitidine
Sensitive
:
A1
No biomarker
MDS
decitabine
Sensitive
:
A1
CALR mutation
MDS
luspatercept-aamt
Sensitive
:
A2
CALR mutation
MDS
lenalidomide
Sensitive
:
A2
MPL W515L
MDS
luspatercept-aamt
Sensitive
:
A2
MPL W515L
MDS
lenalidomide
Sensitive
:
A2
JAK2 V617F
MDS
luspatercept-aamt
Sensitive
:
A2
SF3B1 mutation
MDS
luspatercept-aamt
Sensitive
:
A2
JAK2 V617F
MDS
lenalidomide
Sensitive
:
A2
SF3B1 mutation
MDS
lenalidomide
Sensitive
:
A2
TP53 mutation
MDS
APR-246
Sensitive
:
B
No biomarker
MDS
Hu5F9-G4
Sensitive
:
B
DNMT3A mutation + SF3B1 mutation
MDS
lenalidomide
Resistant
:
B
No biomarker
MDS
MLN4924
Sensitive
:
B
No biomarker
MDS
lenalidomide
Sensitive
:
B
Chr del(5)(q31)
MDS
lenalidomide
Sensitive
:
B
BCR-ABL1 fusion
MDS
imatinib
Sensitive
:
C1
TP53 mutation
MDS
venetoclax
Sensitive
:
C1
TP53 mutation
MDS
CB-839
Sensitive
:
C2
FLT3 mutation
MDS
ARO-002
Sensitive
:
C2
TP53 mutation
MDS
decitabine
Sensitive
:
C2
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our